Patent · US Active

Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2

US9090700B2 · kind B2 · utility

12Cited by

1References

9Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Thomas Friess · Planegg, DE
Max Hasmann · Schwanau, DE
Werner Scheuer · Penzberg, DE

Key dates

Filing date	Nov 16, 2010
Grant date	Jul 28, 2015
Priority date	—
Expiry date	Feb 11, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/24
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides a method of treating a breast cancer disease in a patient who has failed prior treatment with an anti-VEGF antibody, comprising administering to the patient a therapeutically effective amount of an anti-HER2 antibody while continuing said anti-VEGF antibody therapy. The invention also provides corresponding pharmaceutical kits and pharmaceutical compositions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.